Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving ...

Panelists discuss how preparing multiple myeloma patients for treatment involves structured education, emotional support, and proactive symptom management—emphasizing clear communication about the ...

For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs ...

Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even ...

The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable ...

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

Panelists discuss how real-world experience with amivantamab plus lazertinib has shown remarkable responses consistent with trial data, including effectiveness in challenging cases such as ...